Free shipping on all orders over $ 500

Favipiravir

Cat. No. M6264
Favipiravir Structure
Synonym:

T-705

Size Price Availability Quantity
10mg USD 128  USD160 In stock
25mg USD 240  USD300 In stock
50mg USD 400  USD500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis.

Protocol
Cell Experiment
Cell lines MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
Preparation method The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
Concentrations 1000 μg/mL
Incubation time 3 d
Animal Experiment
Animal models Mice infected with influenza virus A/PR/8/34
Formulation 0.5% methylcellulose
Dosages 200 mg/kg/day
Administration p.o.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 157.1
Formula C5H4FN3O2
CAS Number 259793-96-9
Purity >98%
Solubility 31 mg/mL in DMSO
Storage at -20°C
References

[1] Oestereich L, et al. Antiviral Res. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.

[2] Smither SJ, et al. Antiviral Res. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.

Related DNA/RNA Synthesis Products
Supinoxin

Supinoxin (RX-5902) is a potent oral inhibitor of phosphorylated p68 RNA helicase (P-p68) and a first-in-class anti-cancer agent. Supinoxin induced apoptosis and inhibited the growth of TNBC cancer cell lines, with IC50 ranging from 10 nM to 20 nM.

5-Fluorouridine

5-Fluorouridine is a metabolite of 5-fluorouracil, a potent inhibitor of nuclease autocleavage. 5-Fluorouridine binds to total and poly A RNA and has antiproliferative activity. 5-Fluorouridine induces apoptosis (cell death).

Vidarabine monohydrate

Vidarabine is a nucleoside antibiotic with antiviral acitivity that interferes with the synthesis of viral DNA. It is used to treat herpes simplex and varicella zoster viruses.

RG3039

RG3039 (PF-06687859, PF 6687859, Quinazoline 495) is an orally bioavailable and brain-penetrant inhibitor of the mRNA decapping enzyme DcpS with IC50 of 4.2 nM and IC90 of 40 nM, respectively.

JH-RE-06

JH-RE-06 is a potent REV1-REV7 interface inhibitor with an IC50 of 0.78 μM and Kd value of 0.42 μM, disrupting REV1-POL ζ-mediated mutagenic translesion synthesis (TLS).

  Catalog
Abmole Inhibitor Catalog




Keywords: Favipiravir, T-705 supplier, DNA/RNA Synthesis, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.